These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 16505440)

  • 1. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).
    Heinrich MC; McArthur GA; Demetri GD; Joensuu H; Bono P; Herrmann R; Hirte H; Cresta S; Koslin DB; Corless CL; Dirnhofer S; van Oosterom AT; Nikolova Z; Dimitrijevic S; Fletcher JA
    J Clin Oncol; 2006 Mar; 24(7):1195-203. PubMed ID: 16505440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.
    Kubo T; Piperdi S; Rosenblum J; Antonescu CR; Chen W; Kim HS; Huvos AG; Sowers R; Meyers PA; Healey JH; Gorlick R
    Cancer; 2008 May; 112(10):2119-29. PubMed ID: 18338812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclooxygenase-2 and platelet-derived growth factor receptors as potential targets in treating aggressive fibromatosis.
    Signoroni S; Frattini M; Negri T; Pastore E; Tamborini E; Casieri P; Orsenigo M; Da Riva L; Radice P; Sala P; Gronchi A; Bertario L; Pierotti MA; Pilotti S
    Clin Cancer Res; 2007 Sep; 13(17):5034-40. PubMed ID: 17785554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of imatinib mesylate in adjuvant therapy of extra-abdominal desmoid tumors.
    Ioannou M; Demertzis N; Iakovidou I; Kottakis S
    Anticancer Res; 2007; 27(2):1143-7. PubMed ID: 17465254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
    Basciani S; Brama M; Mariani S; De Luca G; Arizzi M; Vesci L; Pisano C; Dolci S; Spera G; Gnessi L
    Cancer Res; 2005 Mar; 65(5):1897-903. PubMed ID: 15753388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
    Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
    J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of KIT exon 10 M541L allelic variant on the response to imatinib in aggressive fibromatosis: analysis of the desminib series by competitive allele specific Taqman PCR technology.
    Dufresne A; Alberti L; Brahmi M; Kabani S; Philippon H; Pérol D; Blay JY
    BMC Cancer; 2014 Aug; 14():632. PubMed ID: 25174682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.
    Heinrich MC; Joensuu H; Demetri GD; Corless CL; Apperley J; Fletcher JA; Soulieres D; Dirnhofer S; Harlow A; Town A; McKinley A; Supple SG; Seymour J; Di Scala L; van Oosterom A; Herrmann R; Nikolova Z; McArthur AG;
    Clin Cancer Res; 2008 May; 14(9):2717-25. PubMed ID: 18451237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity.
    Holtkamp N; Okuducu AF; Mucha J; Afanasieva A; Hartmann C; Atallah I; Estevez-Schwarz L; Mawrin C; Friedrich RE; Mautner VF; von Deimling A
    Carcinogenesis; 2006 Mar; 27(3):664-71. PubMed ID: 16357008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas.
    Do I; Araujo ES; Kalil RK; Bacchini P; Bertoni F; Unni KK; Park YK
    Pathol Res Pract; 2007; 203(3):127-34. PubMed ID: 17298867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.
    Antonescu CR; Besmer P; Guo T; Arkun K; Hom G; Koryotowski B; Leversha MA; Jeffrey PD; Desantis D; Singer S; Brennan MF; Maki RG; DeMatteo RP
    Clin Cancer Res; 2005 Jun; 11(11):4182-90. PubMed ID: 15930355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brief report: activity of imatinib in a patient with platelet-derived-growth-factor receptor positive malignant solitary fibrous tumor of the pleura.
    De Pas T; Toffalorio F; Colombo P; Trifirò G; Pelosi G; Vigna PD; Manzotti M; Agostini M; de Braud F
    J Thorac Oncol; 2008 Aug; 3(8):938-41. PubMed ID: 18670317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate.
    Mace J; Sybil Biermann J; Sondak V; McGinn C; Hayes C; Thomas D; Baker L
    Cancer; 2002 Dec; 95(11):2373-9. PubMed ID: 12436445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
    Yeh CN; Chen TW; Lee HL; Liu YY; Chao TC; Hwang TL; Jan YY; Chen MF
    Ann Surg Oncol; 2007 Mar; 14(3):1123-8. PubMed ID: 17195905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.
    Lee JH; Kim Y; Choi JW; Kim YS
    J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis.
    Gonçalves A; Monges G; Yang Y; Palmerini F; Dubreuil P; Noguchi T; Jacquemier J; Di Stefano D; Delpero JR; Sobol H; Bertucci F
    J Natl Cancer Inst; 2006 Apr; 98(8):562-3. PubMed ID: 16622127
    [No Abstract]   [Full Text] [Related]  

  • 17. Response to imatinib in KIT- and PDGFRA-wild type gastrointestinal stromal associated with neurofibromatosis type 1.
    Lee JL; Kim JY; Ryu MH; Kang HJ; Chang HM; Kim TW; Lee H; Park JH; Kim HC; Kim JS; Kang YK
    Dig Dis Sci; 2006 Jun; 51(6):1043-6. PubMed ID: 16865565
    [No Abstract]   [Full Text] [Related]  

  • 18. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.
    Corless CL; Schroeder A; Griffith D; Town A; McGreevey L; Harrell P; Shiraga S; Bainbridge T; Morich J; Heinrich MC
    J Clin Oncol; 2005 Aug; 23(23):5357-64. PubMed ID: 15928335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model.
    Hwang RF; Yokoi K; Bucana CD; Tsan R; Killion JJ; Evans DB; Fidler IJ
    Clin Cancer Res; 2003 Dec; 9(17):6534-44. PubMed ID: 14695158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of KIT in the management of patients with gastrointestinal stromal tumors.
    Hornick JL; Fletcher CD
    Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.